bioAffinity Technologies

Performance

About bioAffinity Technologies

bioAffinity Technologies develops noninvasive diagnostic tests and targeted cancer therapies with a focus on early detection of lung cancer. The company’s CyPath Lung test analyzes sputum using automated flow cytometry to characterize lung cell populations and assist clinical decision-making for early-stage cancer, aiming to reduce unnecessary invasive procedures. Their work centers on advancing lung cancer detection and personalized treatment strategies, with operations and collaborations described around the United States. Headquartered in the United States, bioAffinity emphasizes laboratory-developed tests and translational research to improve cancer outcomes.